Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 21, 2016

View Archived Issues

Efficacy and safety of ribavirin-free DAA treatments in patients with severe renal impairment

AzurRx BioPharma and Mayoly Spindler launch phase II study of MS-1819-SD

EC grants orphan drug designation to Ra Pharmaceuticals' RA-101495

L807-mts demonstrates promising results in mouse model of Alzheimer's disease

Novel Zika virus infection model in immunocompetent neonatal C57Bl/6 mice

VH-298 is a novel potent and selective chemical probe of hypoxic signaling

Novel animal models presented at the Society for Neuroscience annual meeting

Nippon Boehringer Ingelheim and Astellas launch Micatrio combination tablets in Japan

PharmAkea extends collaboration with Celgene

Omeros patents PDE10A inhibitors

University of North Carolina at Chapel Hill discloses anticancer agents

Shanghai Fochon Pharmaceutical describes CDK4/cyclin D1 and CDK6/cyclin D1 inhibitors

Chinese scientists develop Nav1.7 channel blockers

Laboratorios del Dr. Esteve presents dual sigma1 and mu-opioid receptor ligands

UMC launches phase II program combining DCVax-L and pembrolizumab

Alzheimer's Association grant supports Proclara's development of NPT-088

Athenex to conduct phase Ib study of Oraxol in combination with ramucirumab

Apricus plans for Vitaros NDA resubmission next year

Medicure to acquire majority interest in Apicore

Novartis acquires Selexys Pharmaceuticals

Aska Pharmaceutical ready to launch Rifxima tablets in Japan

European Commission approves Trisenox for first-line treatment of low to intermediate risk APL

Boehringer Ingelheim launches idarucizumab as reversal agent for dabigatran in Japan

GSK submits NDA for closed triple combination therapy for COPD

Bristol-Myers Squibb launches elotuzumab in Japan

MSD K.K. launches elbasvir and grazoprevir in Japan

Bilanoa launched in Japan

Otsuka launches Iclusig in Japan

Laboratoris Sanifit reports clinical data on SNF-472

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...